1. Search Result
Search Result
Results for "

neoplastic diseases

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Inhibitory Antibodies

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99452

    SNDX-6352

    c-Fms Inflammation/Immunology Cancer
    Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases .
    Axatilimab
  • HY-43521

    Target Protein Ligand-Linker Conjugates Btk STAT Inflammation/Immunology Cancer
    Ibrutinib-MPEA is an orally active, blood-brain barrier permeable inhibitor of BTK and STAT5. As a derivative of Ibrutinib (HY-10997) conjugated with a PROTAC linker, Ibrutinib-MPEA allows the synthesis of a series of PROTAC molecules. Ibrutinib-MPEA significantly reduces the proliferation of neoplastic mast cells and primary mastocytoma cells by inducing apoptosis and inhibiting IgE-dependent histamine release. Ibrutinib-MPEA is applicable to the research of canine mast cell tumors, cerebral ischemia/reperfusion injury in diabetic mice, and neuroinflammation-related diseases .
    Ibrutinib-MPEA
  • HY-W009776

    Suberohydroxamic acid; SBHA

    HDAC Apoptosis Cancer
    Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) is a competitive and cell-permeable HDAC1 and HDAC3 inhibitor with ID50 values of 0.25 μM and 0.30 μM, respectively .Suberoyl bis-hydroxamic acid renders MM cells susceptible to apoptosis and facilitates the mitochondrial apoptotic pathways .Suberoyl bis-hydroxamic acid can be used for the study of medullary thyroid carcinoma (MTC) .
    Suberoyl bis-hydroxamic acid
  • HY-130332

    Macrophage migration inhibitory factor (MIF) Cancer
    Mitomycin A is an antitumor agent. Mitomycin A inhibits the spontaneous migration of mouse monocytes. Mitomycin A inhibits the production of MIF (Migration Inhibition Factor) by human lymphocytes. Mitomycin A can be used in the research of tumor diseases .
    Mitomycin A
  • HY-176463

    NEKs Cancer
    Nek2/Hec1-IN-3 (Compound 11-28) is a Hec1/Nek2 interaction inhibitor. Nek2/Hec1-IN-3 disrupts Nek2/Hec1 binding and can be used for research of neoplastic diseases .
    Nek2/Hec1-IN-3
  • HY-144452

    Proteasome Cancer
    Immunoproteasome inhibitor 1 is a potent, reversible, time-independent immunoproteasome and proteasome inhibitor (Kis of 1.18, 0.27, 1.91 μM in β5c, β1i, β5i submits, respectively). Immunoproteasome inhibitor 1 can be used for the research of certain neoplastic diseases .
    Immunoproteasome inhibitor 1
  • HY-141431

    E1/E2/E3 Enzyme Inflammation/Immunology Cancer
    Cbl-b-IN-2 (Example 8) is an orally bioavailable compound, can inhibit the E3 enzyme Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases amenable to immune system modulation. Cbl-b-IN-2 (Example 8) also may be administered to an individual with cancer, either alone or as part of a combination, with one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation agent .
    Cbl-b-IN-2
  • HY-143208

    DNA/RNA Synthesis Cancer
    HOE 33187-O-CONH-PEG4-phenol-thiophenone-NHPh-COOEt has inhibitory activity against pre-miR-21 RNA. HOE 33187-O-CONH-PEG4-phenol-thiophenone-NHPh-COOEt has the potential for the research of neoplastic disease such as cancer and especially cancers expressing miR-21 (extracted from patent WO2021087084A1, compound 25) .
    HOE 33187-O-CONH-PEG4-phenol-thiophenone-NHPh-COOEt
  • HY-10132

    Caspase Cancer
    CASP3 activator 1 is an activator of executioner procaspases 3, 6 and 7. CASP3 activator 1 can be used for the research of cancer, neoplastic diseases .
    CASP3 activator 1
  • HY-182375

    LPL Receptor Inflammation/Immunology
    (R)-SLB1122168 free base, an isomer of SLB1122168 free base (HY-182375A), is a spinster homolog 2 (SPNS2) inhibitor with an IC50 ≤2 μM .
    (R)-SLB1122168 free base
  • HY-182375A

    LPL Receptor Inflammation/Immunology Cancer
    SLB1122168 free base is a Spinster Homolog 2 (Spns2) inhibitor. SLB1122168 free base inhibits Spns2-mediated sphingosine-1-phosphate (S1P) release with an IC50 of 94 nM. SLB1122168 free base induces lymphopenia in circulating lymphocytes in mice and rats .
    SLB1122168 free base

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: